免疫检查点抑制剂相关葡萄膜炎:跨恶性肿瘤与药物类别的比较分析
这项回顾性多中心队列研究经倾向评分匹配后纳入黑色素瘤与肺癌各16,834例,比较不同恶性肿瘤及ICI药物类别间新发非感染性葡萄膜炎(NIU)风险。黑色素瘤患者24个月内NIU风险显著高于肺癌(1.10% vs 0.18%;RR 6.17,95%CI 4.20-9.08),排除伊匹木单抗/纳武利尤单抗后风险仍升高。抗PD-1与抗PD-L1单药间风险无显著差异。
要点
- 黑色素瘤患者ICI相关NIU风险显著高于肺癌,排除伊匹木单抗/纳武利尤单抗后仍升高。
- 肾细胞癌的NIU风险在很大程度上由伊匹木单抗/纳武利尤单抗暴露驱动。
- 抗PD-1与抗PD-L1单药间NIU风险无显著差异(0.26% vs 0.20%;RR 1.33,95%CI 0.89-1.99)。
核心结论
- 恶性肿瘤类型与ICI亚类均影响ICI相关葡萄膜炎风险。
- 黑色素瘤具有独立于伊匹木单抗/纳武利尤单抗暴露的内在较高风险,而肾细胞癌风险似乎主要由伊匹木单抗/纳武利尤单抗驱动。
- ICI相关葡萄膜炎的病理生理由药物与疾病双重因素驱动,黑色素瘤患者启动ICI时需密切监测。
研究设计与样本
- 回顾性、多中心临床队列研究,针对转移性黑色素瘤、肺癌、肾细胞癌、尿路上皮癌、肝细胞癌、霍奇金淋巴瘤或非黑色素瘤皮肤癌的成人患者。
- 对人口学、合并症及社会经济因素进行倾向评分匹配。
- 暴露为任何类别ICI药物处方(抗PD-1、抗PD-L1或抗CTLA-4)。
- 主要结局为首次ICI处方后24个月内新发非感染性葡萄膜炎(NIU),计算相对风险(RR)及95%置信区间(CI)。
- 匹配后纳入黑色素瘤与肺癌患者各16,834例。
主要发现
- 黑色素瘤患者NIU风险高于肺癌(1.10% vs 0.18%;RR 6.17;95%CI 4.20-9.08)。
- 排除伊匹木单抗/纳武利尤单抗后,黑色素瘤仍与风险升高相关(0.53% vs 0.16%;RR 3.40;95%CI 1.68-6.88)。
- 跨恶性肿瘤比较中,黑色素瘤相对其他队列 consistently 显示风险升高。
- 肺癌相比肾细胞癌显示边缘性风险降低(0.19% vs 0.36%;RR 0.53;95%CI 0.31-0.90),但排除伊匹木单抗/纳武利尤单抗后不显著。
- 抗PD-1药物与抗PD-L1药物间NIU风险无显著差异(0.26% vs 0.20%;RR 1.33;95%CI 0.89-1.99);抗CTLA-4药物因单药使用有限未能比较。
关键数值与推荐
- 黑色素瘤 vs 肺癌:NIU发生率1.10% vs 0.18%,RR 6.17(95%CI 4.20-9.08)。
- 排除伊匹木单抗/纳武利尤单抗后:黑色素瘤 vs 肺癌 NIU发生率0.53% vs 0.16%,RR 3.40(95%CI 1.68-6.88)。
- 肺癌 vs 肾细胞癌:NIU发生率0.19% vs 0.36%,RR 0.53(95%CI 0.31-0.90),排除伊匹木单抗/纳武利尤单抗后不显著。
- 抗PD-1 vs 抗PD-L1:NIU发生率0.26% vs 0.20%,RR 1.33(95%CI 0.89-1.99)。
- 主要结局定义为首次ICI处方后24个月内新发NIU。
临床怎么用
- 对启动ICI治疗的黑色素瘤患者应加强眼科监测,因其NIU风险内在较高。
- 肾细胞癌患者的NIU风险需结合伊匹木单抗/纳武利尤单抗暴露评估,提示药物特异性因素。
- 抗PD-1与抗PD-L1单药间NIU风险未见显著差异,药物选择时可参考但需结合其他因素。
局限性
- 抗CTLA-4药物因单药使用有限未能进行类别比较。
- 研究为回顾性设计,可能存在残留混杂。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes. DESIGN: Retrospective, multicenter clinical cohort study. SUBJECTS: Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, or nonmelanoma skin cancer. Propensity score matching was performed for demographics, comorbidities, and socioeconomic factors. EXPOSURES: Prescription of an ICI agent of any class (anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4]). MAIN OUTCOME MEASURES: The primary outcome was new-onset NIU within 24 months of first ICI prescription. Relative risks (RR) with 95% confidence intervals (CIs) were calculated. Subgroup analyses compared outcomes across malignancies, with and without ipilimumab or nivolumab exposure, and between ICI subclasses when used in monotherapy. RESULTS: After matching, 16,834 patients with melanoma and 16,834 with lung cancer were included. Melanoma patients had a higher risk of NIU compared with lung cancer (1.10% vs 0.18%; RR, 6.17; 95% CI, 4.20-9.08). Excluding ipilimumab/nivolumab, melanoma remained associated with increased risk (0.53% vs 0.16%; RR, 3.40; 95% CI, 1.68-6.88). Across malignancies, melanoma consistently demonstrated elevated risk relative to other cohorts. Lung cancer showed borderline decreased risk compared to RCC (0.19% vs 0.36%; RR, 0.53; 95% CI, 0.31-0.90), but this effect was not significant after excluding ipilimumab/nivolumab. In drug-class analyses, anti-PD-1 agents did not demonstrate a significantly different risk of NIU compared with anti-PD-L1 agents (0.26% vs 0.20%; RR, 1.33; 95% CI, 0.89-1.99). Anti-cytotoxic T-lymphocyte-associated protein 4 agents could not be compared due to limited use as monotherapy. CONCLUSIONS: Both malignancy type and ICI subclass influence the risk of ICI-associated uveitis. Melanoma carries an intrinsically higher risk independent of ipilimumab/nivolumab exposure, whereas RCC's risk appears largely ipilimumab/nivolumab-driven. These findings underscore the need for careful monitoring of melanoma patients initiating ICIs and suggest that the pathophysiology of ICI-related uveitis is driven by both drug- and disease-specific factors.
引用
- Bellanda V, Schulgit MJ, Hassan KA, et al. Immune Checkpoint Inhibitor-Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes. Am J Ophthalmol. 2026. PMID: 42229563. doi:10.1016/j.ajo.2026.05.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。